Interleukin 2 (IL-2) variants engineered for increased IL-2 receptor alpha-subunit affinity exhibit increased potency arising from a cell surface ligand reservoir effect.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Molecular Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1124/mol.66.4.864PMID 15385640
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interleukin-2 mutants with enhanced alpha-receptor subunit binding affinity.

  2003influential reference
• Effect of pegylation on pharmaceuticals

  2003cited by this paper
• Interleukin-2 and interleukin-15: immunotherapy for cancer.

  2002influential reference
• IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells.

  2002influential reference
• Analysis of the role of the interleukin-2 receptor gamma chain in ligand binding.

  2002cited by this paper
• Normal T, B, and NK cell counts in healthy donors at 1 year after blood stem cell harvesting.

  2000cited by this paper
• Computational Model for Effects of Ligand/Receptor Binding Properties on Interleukin‐2 Trafficking Dynamics and T Cell Proliferation Response

  2000influential reference
• Surface and Intracellular Interleukin‐2 Receptor Expression on Various Resting and Activated Populations Involved in Cell‐Mediated Immunity in Human Peripheral Blood

  2000cited by this paper
• High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

  1999cited by this paper
• Mechanism of Activation of the GM‐CSF, IL‐3, and IL‐5 Family of Receptors

  1998cited by this paper
• Biology of the interleukin-2 receptor.

  1998cited by this paper
• [Interleukin-2 receptor].

  1997cited by this paper
• Interleukin 2 and its receptors: recent advances and new immunological functions.

  1996cited by this paper
• Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

  1995cited by this paper
• Pseudo-high affinity interleukin 2 (IL-2) receptor lacks the third component that is essential for functional IL-2 binding and signaling

  1992cited by this paper
• Cyclosporin A inhibits the interleukin 2 receptor α chain gene transcription but not its cell surface expression: the α chain stability can explain this discrepancy

  1990cited by this paper
• Pharmacokinetics of recombinant interleukin 2 in humans.

  1990influential reference
• The interleukin 2 receptor.

  1989cited by this paper
• Establishment of an interleukin 2-dependent human T cell line from a patient with T cell chronic lymphocytic leukemia who is not infected with human T cell leukemia/lymphoma virus.

  1987cited by this paper

• Regulating IL-2 immune signaling function via a core allosteric structural network.

  2024cites this paper
• Molecular Engineering of Interleukin-2 for Enhanced Therapeutic Activity in Autoimmune Diseases

  2023cites this paper
• The T-Cell Growth Factor Interleukin-2, Which Is Occasionally Targeted by Autoantibodies, Qualifies as Drug for the Treatment of Allergy, Autoimmunity, and Cancer: Collegium Internationale Allergologicum (CIA) Update 2024

  2023cites this paper
• Proximity-enabled covalent binding of IL-2 to IL-2Rα selectively activates regulatory T cells and suppresses autoimmunity

  2023cites this paper
• Cellular landscaping of cisplatin resistance in cervical cancer.

  2022cites this paper
• Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist

  2020cites this paper
• Persistent IL-2 Receptor Signaling by IL-2/CD25 Fusion Protein Controls Diabetes in NOD Mice by Multiple Mechanisms

  2020cites this paper
• IL-2 and Beyond in Cancer Immunotherapy

  2018cites this paper
• IL-2/CD25: A Long-Acting Fusion Protein That Promotes Immune Tolerance by Selectively Targeting the IL-2 Receptor on Regulatory T Cells

  2018cites this paper
• Mapping Determinants of Cytokine Signaling via Protein Engineering

  2018cites this paper
• Prospects of IL-2 in Cancer Immunotherapy

  2018cites this paper
• Oscillatory IL-2 stimulus reveals pertinent signaling timescales of T cell responsiveness

  2018cites this paper
• The challenges and molecular approaches surrounding interleukin-2-based therapeutics in cancer

  2018cites this paper
• Affinity maturation of novel human antibodies for cancer immunotherapy, by yeast surface display technology

  2017influential citation
• Protein Engineering by Combined Computational and In Vitro Evolution Approaches.

  2016cites this paper
• Role of IL-2 in cancer immunotherapy

  2016cites this paper
• Inflammatory Bowel Disease: How Effective Is TNF-α Suppression?

  2016cites this paper
• Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms.

  2015cites this paper
• IL-2Rα mediates temporal regulation of IL-2 signaling and enhances immunotherapy

  2015cites this paper
• Instructive roles for cytokine-receptor binding parameters in determining signaling and functional potency

  2015cites this paper
• Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution

  2015cites this paper
• Protein Engineering and Selection Using Yeast Surface Display.

  2015cites this paper
• Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy

  2014cites this paper
• Protein selection using yeast surface display.

  2013cites this paper
• Mathematical Model of the Roles of T Cells in Inflammatory Bowel Disease

  2013influential citation
• Mechanistic Model of Natural Killer Cell Proliferative Response to IL-15 Receptor Stimulation

  2013cites this paper
• Beyond antibodies: using biological principles to guide the development of next-generation protein therapeutics.

  2013cites this paper
• Mathematical Model of the Roles of T Cells in Inflammatory Bowel Disease

  2013influential citation
• Exploiting a natural conformational switch to engineer an Interleukin-2 superkine

  2012cites this paper
• Understanding cytokine and growth factor receptor activation mechanisms

  2012cites this paper
• Engineering Leukocyte Integrins For Therapeutic Development Against Inflammatory Diseases

  2012cites this paper
• Mathematical Models of the Role of IL-2 in the Interactions Between Helper and Regulatory CD4+ T Cells

  2011cites this paper
• Affinity Maturation Approaches for Antibody Lead Optimization

  2011cites this paper
• Combinatorial libraries against libraries for selecting neoepitope activation-specific antibodies

  2010cites this paper
• Engineering Of Therapeutic Proteins

  2009cites this paper
• Biosensor detection systems: engineering stable, high-affinity bioreceptors by yeast surface display.

  2009cites this paper
• Developing therapeutic proteins by engineering ligand-receptor interactions.

  2008cites this paper
• A decade of yeast surface display technology: where are we now?

  2008cites this paper
• Enhanced insulin‐like growth factor‐I (IGF‐I) cell association at reduced pH is dependent on IGF binding protein‐3 (IGFBP‐3) interaction

  2007cites this paper
• Optimizing the affinity and specificity of proteins with molecular display.

  2006cites this paper
• Improved mutants from directed evolution are biased to orthologous substitutions.

  2006cites this paper
• Regulation of Insulin-Like Growth Factor-I (IGF-I) Delivery by IGF Binding Proteins and Receptors

  2006cites this paper
• Integrating cell-level kinetic modeling into the design of engineered protein therapeutics

  2005cites this paper
• Interleukin-2 family cytokines: potential for therapeutic immmunoregulation

  2005cites this paper
• Interleukin-2 Engineering for improved therapeutic effectiveness

  2004cites this paper